Guidelines for best practices in monitoring established coeliac disease in adult patients
© 2023. Springer Nature Limited..
Coeliac disease (CeD) is an immunological disease triggered by the consumption of gluten contained in food in individuals with a genetic predisposition. Diagnosis is based on the presence of small bowel mucosal atrophy and circulating autoantibodies (anti-type 2 transglutaminase antibodies). After diagnosis, patients follow a strict, life-long gluten-free diet. Although the criteria for diagnosis of this disease are well defined, the monitoring phase has been studied less and there is a lack of specific guidelines for this phase. To develop a set of clinical guidelines for CeD monitoring, we followed the Grading of Recommendations Assessment, Development and Evaluation methodology. Statements and recommendations with the level of evidence were developed and approved by the working group, which comprised gastroenterologists, pathologists, dieticians and biostatisticians. The proposed guidelines, endorsed by the North American and European coeliac disease scientific societies, make recommendations for best practices in monitoring patients with CeD based on the available evidence. The evidence level is low for many topics, suggesting that further research in specific aspects of CeD would be valuable. In conclusion, the present guidelines support clinicians in improving CeD treatment and follow-up and highlight novel issues that should be considered in future studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Nature reviews. Gastroenterology & hepatology - 21(2024), 3 vom: 18. März, Seite 198-215 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elli, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41575-023-00872-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366012452 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366012452 | ||
| 003 | DE-627 | ||
| 005 | 20240304232133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41575-023-00872-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM366012452 | ||
| 035 | |a (NLM)38110546 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elli, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines for best practices in monitoring established coeliac disease in adult patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a Coeliac disease (CeD) is an immunological disease triggered by the consumption of gluten contained in food in individuals with a genetic predisposition. Diagnosis is based on the presence of small bowel mucosal atrophy and circulating autoantibodies (anti-type 2 transglutaminase antibodies). After diagnosis, patients follow a strict, life-long gluten-free diet. Although the criteria for diagnosis of this disease are well defined, the monitoring phase has been studied less and there is a lack of specific guidelines for this phase. To develop a set of clinical guidelines for CeD monitoring, we followed the Grading of Recommendations Assessment, Development and Evaluation methodology. Statements and recommendations with the level of evidence were developed and approved by the working group, which comprised gastroenterologists, pathologists, dieticians and biostatisticians. The proposed guidelines, endorsed by the North American and European coeliac disease scientific societies, make recommendations for best practices in monitoring patients with CeD based on the available evidence. The evidence level is low for many topics, suggesting that further research in specific aspects of CeD would be valuable. In conclusion, the present guidelines support clinicians in improving CeD treatment and follow-up and highlight novel issues that should be considered in future studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Leffler, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Cellier, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Lebwohl, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Ciacci, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Schumann, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lundin, Knut E A |e verfasserin |4 aut | |
| 700 | 1 | |a Chetcuti Zammit, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Sidhu, Reena |e verfasserin |4 aut | |
| 700 | 1 | |a Roncoroni, Leda |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Julio C |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Anne R |e verfasserin |4 aut | |
| 700 | 1 | |a Dennis, Melinda |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Marie E |e verfasserin |4 aut | |
| 700 | 1 | |a Rostami, Kamran |e verfasserin |4 aut | |
| 700 | 1 | |a Khater, Sherine |e verfasserin |4 aut | |
| 700 | 1 | |a Comino, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Cebolla, Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Branchi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Verdu, Elena F |e verfasserin |4 aut | |
| 700 | 1 | |a Stefanolo, Juan Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Randi |e verfasserin |4 aut | |
| 700 | 1 | |a Bergman-Golden, Sheba |e verfasserin |4 aut | |
| 700 | 1 | |a Trott, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Scudeller, Luigia |e verfasserin |4 aut | |
| 700 | 1 | |a Zingone, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Scaramella, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, David S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews. Gastroenterology & hepatology |d 2009 |g 21(2024), 3 vom: 18. März, Seite 198-215 |w (DE-627)NLM187650985 |x 1759-5053 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:3 |g day:18 |g month:03 |g pages:198-215 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41575-023-00872-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 3 |b 18 |c 03 |h 198-215 | ||